Salner, Andrew, MD, FACR, FASTRO
Hartford HealthCare Medical Group

Andrew Salner, MD, FACR, FASTRO

Radiation Oncology

Location Information

  • Hartford HealthCare Cancer Institute
    85 Retreat Avenue
    Hartford, CT 06106


About Andrew Salner, MD, FACR, FASTRO

  • Title
    Medical Director, Hartford HealthCare Cancer Institute at Hartford Hospital
  • Gender
  • Language
    Providing the best care to our patients and their companions requires communicating in a way everyone understands. Interpreter services are available 24 hours a day, 7 days a week, 365 days a year. All spoken languages are available, as well as American Sign Language (AS/L)
  • Specialties
    Not Currently Accepting New Patients

    Radiation Oncology

  • Areas of Expertise
    Brachytherapy, Brain Cancer, Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Head & Neck Cancers, Lung Cancer, Lymphoma, Melanoma, Prostate Cancer, Skin Cancer, Thoracic Cancers


  • Medical SchoolBrown University School of Medicine

    ResidencyHartford Hospital
    Joint Center for Radiation Therapy, Harvard Medical School (Boston)
    Harvard School of Medicine

    UndergraduateBrown University

  • Faculty Appointments

    University of Connecticut School of Medicine, Associate Clinical Professor

  • Professional Organizations

    American Society for Radiation Oncology, Fellow
    American College of Radiology, Fellow
    Hartford Hospital Board of Directors
    Connecticut Cancer Partnership Board of Directo
    American Society of Clinical Oncology
    American Society for Therapeutic Radiology and Oncology


Hartford HealthCare Cancer Specialists have delivered a new and exciting therapy to treat patients diagnosed with a relatively rare form of cancer.

Joining us is Dr. Andrew Salner, Radiation Oncologist and Medical Director of the Hartford HealthCare Cancer Institute at Hartford Hospital, who helped to oversee the team of individuals making the treatment possible…Good Evening Dr. Salner…

Good Evening!

Q. This particular therapy is for the treatment of gastrointestinal neuro-endocrine tumors - first explain what these tumors are…

A. These are a relatively rare group of tumors that arise from cells that have specific hormone producing functions in the body. The abdominal neuro-endocrine tumors arise in the stomach, small intestine, appendix, large intestine and pancreas. They are also called carcinoid tumors, and can in selected patients cause carcinoid syndrome characterized by flushing, sweats, and diarrhea. They tend to grow slowly though they vary in their level of malignancy, and can ultimately spread to other parts of the body.

Q. Previously, there were limited treatment options available for this type of cancer...tell us about this targeted treatment…I understand it is a radioactive drug? How does it work in the body…

A. These tumors, if localized can be removed by surgery. If more advanced, they have been a conundrum in that we can block some of the abnormal hormone production with medications to lessen symptoms but don’t have a good tumor shrinking therapy. Conventional chemotherapy agents do not work effectively. This new therapy, lutathera, consist of 2 parts, one that specifically binds to the receptor on the cancer cell, and the other is the radioactive molecule that delivers a potentially lethal punch to the cancer cell only.

Q. I understand there is a great deal of complexity in administering this type of treatment…correct?

A. This intravenously administered medication can injure the kidneys if not delivered with a protective amino acid IV solution and with a set of anti-nausea medications as well. It takes a team of infusion nurses, pharmacists, nuclear medicine, and radiation safety staff to do give the 6-8 hour therapy well.

Q. Since Lutathera is part of a new class of drugs, is it likely that other drugs like this will emerge for other tumor types?

A. This new class of drugs, Peptide Receptor Radionuclide Therapy, or PRRT, already has new agents in testing that target other types of cancer cells. I am extremely optimistic that Lutathera opens a door for new and exciting cancer therapies for patients otherwise challenging to treat effectively.

Thank you, Dr. Salner for sharing this important information with our viewers. If you would like more information call the Hartford HealthCare Cancer Institute at 1-855-255-6181.

Dr. Salner has been a volunteer for the American Cancer Society (ACS) since 1981. He has served on and chaired numerous unit, division, and national ACS committees and boards.

Dr. Salner has received numerous awards and honors including the American Cancer Society, St. George Medal and Lane Adams Quality of Life Award. He was awarded a Fellowship in the American College of Radiology and has written numerous articles and book chapters.

His current areas of research include cancer communications for patients and families, cancer early detection for the under-served and preparedness for radio-logic terrorism.



Aetna, Anthem, BCBS Medicare, CarePartners of Connecticut, Cigna Healthcare, Colonial Cooperative Care, Community Health Network of Connecticut, Inc., Connecticare, Connecticare Commercial, Connecticare Medicare, Corvel, Coventry, Essence Healthcare, Evercare, First Health Group Corp., Focus, Harvard Pilgrim, Health Connecticut, Health Direct, Health New England, Healthy Connecticut, HMC/ Northeast Healthcare, Multiplan, Northeast Health Direct, One Health Plan/ Great-West Healthcare, Oxford Health Plans, Prime Health Services, Private Health Care Systems, Inc., Senior Whole Health, United Healthcare, WellCare of Connecticut, Inc.
This information is subject to change at any time. Please check with your insurance provider before scheduling your appointment or receiving services to confirm they are a participating member of the Hartford HealthCare network.
Back to Top